How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
One approach to experimental science involves creating hypotheses, then testing them by varying one or more independent variables, and assessing the effects of this variation on the processes of interest. We use this strategy to compare the intellectual status and available evidence for two models or views of mechanisms of transmembrane drug transport into intact biological cells. One (BDII) asserts that lipoidal phospholipid Bilayer Diffusion Is Important, while a second (PBIN) proposes that in normal intact cells Phospholipid Bilayer diffusion Is Negligible (i.e., may be neglected quantitatively), because evolution selected against it, and with transmembrane drug transport being effected by genetically encoded proteinaceous carriers or pores, whose "natural" biological roles, and substrates are based in intermediary metabolism. Despite a recent review elsewhere, we can find no evidence able to support BDII as we can find no experiments in intact cells in which phospholipid bilayer diffusion was either varied independently or measured directly (although there are many papers where it was inferred by seeing a covariation of other dependent variables). By contrast, we find an abundance of evidence showing cases in which changes in the activities of named and genetically identified transporters led to measurable changes in the rate or extent of drug uptake. PBIN also has considerable predictive power, and accounts readily for the large differences in drug uptake between tissues, cells and species, in accounting for the metabolite-likeness of marketed drugs, in pharmacogenomics, and in providing a straightforward explanation for the late-stage appearance of toxicity and of lack of efficacy during drug discovery programmes despite macroscopically adequate pharmacokinetics. Consequently, the view that Phospholipid Bilayer diffusion Is Negligible (PBIN) provides a starting hypothesis for assessing cellular drug uptake that is much better supported by the available evidence, and is both more productive and more predictive.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020124 · Cited by 10,505
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430 · cited 1×
“The Biopharmaceutics Classification System (BCS), based on the work of Amidon and colleagues (e.g., Amidon et al., 1995; Dahan et al., 2009; Chen et al., 2011), was developed to indicate a “bioequivalence,” and divides drugs into four classes based on their solubility and presumed (human jejunal)…”
MethodWhy Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · CHANCE · doi:10.1080/09332480.2005.10722754 · Cited by 4,702 · cited 2×
“REVIEW ARTICLE published: 31 October 2014 doi: 10.3389/fphar.2014.00231 How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion”
BackgroundInfluentialGolbraikh, A., & Tropsha, A. (2002) · Journal of Molecular Graphics and Modelling · doi:10.1016/s1093-3263(01)00123-1 · Cited by 3,735 · cited 1×
“However, this approach to QSAR/QSPR has since been questioned seriously (e.g., Golbraikh and Tropsha, 2002; Cronin and Schultz, 2003; Eriksson et al., www.frontiersin.org October 2014 | Volume 5 | Article 231 | 5 2003; Golbraikh et al., 2003; Tropsha et al., 2003; Broadhurst and Kell, 2006;…”
MethodMembrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403 · cited 2×
“…2014; Sprowl and Sparreboom, 2014) have been highlighting, Smith and colleagues recently published a review (Smith et al., 2014) that claims that the hypothesis that drugs are usually transported into cells via protein carriers is “not a sound scientific principle and lacks experimental evidence.””
BackgroundSLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
How fast-folding proteins fold
Lindorff-Larsen, K., Piana, S., Dror, R. O., & Shaw, D. E. (2011) · Science · doi:10.1126/science.1208351 · Cited by 1,980
Enzyme promiscuity: A mechanistic and evolutionary perspective
Tawfik, O. K. A. D. S. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-030409-143718 · Cited by 1,355
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Sites of alcohol and volatile anaesthetic action on GABAA and glycine receptors
Mihic, S. J., Ye, Q., Wick, M. J., Koltchine, V. V., Krasowski, M. D., Finn, S. E., Mascia, M. P., Valenzuela, C. F., Hanson, K. K., Greenblatt, E. P., et al. (1997) · Nature · doi:10.1038/38738 · Cited by 1,219
Polypharmacology: Challenges and Opportunities in Drug Discovery: Miniperspective
Anighoro, A., Bajorath, J., & Rastelli, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006463 · Cited by 1,131
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
A community-driven global reconstruction of human metabolism
Thiele, I., Swainston, N., Fleming, R. M. T., Hoppe, A., Sahoo, S., Aurich, M. K., Haraldsdottir, H., Mo, M. L., Rolfsson, O., Stobbe, M. D., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2488 · Cited by 1,019 · cited 1×
“Counter: molecular dynamics (and other) simulations are a highly important part of science (and engineering), and these and other computational analyses will become increasingly so (Hey et al., 2009), not least in systems biology (Kell and Knowles, 2006; Herrgård et al., 2008; Thiele et al., 2013).”
BackgroundSelf-citationPlasma membrane phosphoinositide organization by protein electrostatics
McLaughlin, S., & Murray, D. (2005) · Nature · doi:10.1038/nature04398 · Cited by 868
PARSEGIAN, A. (1969) · Nature · doi:10.1038/221844a0 · Cited by 854 · cited 1×
“…membranes (Jain, 1972; Tien, 1974; Tien and Ottova-Leitmannova, 2003) can only be due to aqueous pores because the Born charging energy is so large that it is inconceivable that Na+ and Cl− ions pass through a membrane dielectric with a permittivity of ∼2–4 (Parsegian, 1969; Bordi et al., 1999).”
BackgroundRational selection of training and test sets for the development of validated QSAR models
Golbraikh, A., Shen, M., Xiao, Z., Xiao, Y.-D., Lee, K.-H., & Tropsha, A. (2003) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1025386326946 · Cited by 712 · cited 1×
“…(e.g., Golbraikh and Tropsha, 2002; Cronin and Schultz, 2003; Eriksson et al., www.frontiersin.org October 2014 | Volume 5 | Article 231 | 5 2003; Golbraikh et al., 2003; Tropsha et al., 2003; Broadhurst and Kell, 2006; Tropsha, 2010), and was before (Kell and Sonnleitner, 1995), as the failure…”
BackgroundPhase II and Phase III attrition rates 2011–2012
Arrowsmith, J., & Miller, P. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4090 · Cited by 697
Inhalational anesthetics activate two-pore-domain background K+ channels
Patel, A. J., Honoré, E., Lesage, F., Fink, M., Romey, G., & Lazdunski, M. (1999) · Nature Neuroscience · doi:10.1038/8084 · Cited by 655
Systematic discovery of multicomponent therapeutics
Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620
Herrgård, M. J., Swainston, N., Dobson, P., Dunn, W. B., Arga, K. Y., Arvas, M., Blüthgen, N., Borger, S., Costenoble, R., Heinemann, M., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1492 · Cited by 588 · cited 1×
“Counter: molecular dynamics (and other) simulations are a highly important part of science (and engineering), and these and other computational analyses will become increasingly so (Hey et al., 2009), not least in systems biology (Kell and Knowles, 2006; Herrgård et al., 2008; Thiele et al., 2013).”
BackgroundSelf-citationDo general anaesthetics act by competitive binding to specific receptors?
Franks, N. P., & Lieb, W. R. (1984) · Nature · doi:10.1038/310599a0 · Cited by 572 · cited 3×
“Frontiers in Pharmacology | Drug Metabolism and Transport October 2014 | Volume 5 | Article 231 | 4 in mammalian anesthesia as it is not in fact present in mammals) (Franks and Lieb, 1984).”
BackgroundInfluentialJurd, R., Arrasa, M., Lambert, S., Drexler, B., Siegwart, R., Crestani, F., Zaugg, M., Vogt, K. E., Ledermann, B., Antkowiak, B., et al. (2003) · The FASEB Journal · doi:10.1096/fj.02-0611fje · Cited by 558
Kell, D. B., & Oliver, S. G. (2004) · BioEssays · doi:10.1002/bies.10385 · Cited by 535 · cited 4×
“…aspect of the hypothesis-driven approach, and note that we do also recognize the great (and perhaps greater) value of data-driven approaches (Kell and Oliver, 2004), is the view that a good theory or hypothesis has predictive power both for existing data and for other experiments not yet…”
BackgroundResultInfluentialSelf-citationTREK-1, a K+ channel involved in neuroprotection and general anesthesia
Heurteaux, C., Guy, N., Laigle, C., Blondeau, N., Duprat, F., Mazzuca, M., Lang‐Lazdunski, L., Widmann, C., Zanzouri, M., Romey, G., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600234 · Cited by 534
Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?
Dobson, P. D., & Kell, D. B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2438 · Cited by 475 · cited 5×
“We have discussed the extensive literature of general anesthetics many times (Dobson and Kell, 2008; Dobson et al., 2009a,b; Kell and Dobson, 2009; Kell et al., 2011, 2013; Kell, 2013; Kell and Goodacre, 2014), and the available data show clearly the involvement of a variety of proteins such as…”
BackgroundInfluentialSelf-citationCan we rationally design promiscuous drugs?
HOPKINS, A., MASON, J., & OVERINGTON, J. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.01.013 · Cited by 469
X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel
Nury, H., Van Renterghem, C., Weng, Y., Tran, A., Baaden, M., Dufresne, V., Changeux, J.-P., Sonner, J. M., Delarue, M., & Corringer, P.-J. (2011) · Nature · doi:10.1038/nature09647 · Cited by 412 · cited 1×
“…of interaction of general anesthetics with a number of their target membrane proteins are now known with molecular resolution, including their variation in mutant forms of the same proteins (that correlate with changes in anesthetics potency—see e.g., Nury et al., 2011; Stansfeld and Sansom, 2011).”
BackgroundRostami-Hodjegan, A. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.65 · Cited by 331
Atomic-level description of ubiquitin folding
Piana, S., Lindorff-Larsen, K., & Shaw, D. E. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218321110 · Cited by 326
Marchetti, S., Mazzanti, R., Beijnen, J. H., & Schellens, J. H. M. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-927 · Cited by 284 · cited 1×
“…indicating that they each have known transporter interactions, as follows: testosterone (Hamada et al., 2008; Sharifi et al., 2008), warfarin (Marchetti et al., 2007), dexamethasone (Polli et al., 2001; Schwab et al., 2003; Uchida et al., 2011a), raffinose (Tyx et al., 2011), metoprolol…”
BackgroundThe TREK K2P channels and their role in general anaesthesia and neuroprotection
Franks, N. P., & Honoré, E. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.09.003 · Cited by 214
Animal versus human oral drug bioavailability: Do they correlate?
Musther, H., Olivares-Morales, A., Hatley, O. J. D., Liu, B., & Rostami Hodjegan, A. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.08.018 · Cited by 211
Elsby, R., Hilgendorf, C., & Fenner, K. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.163 · Cited by 198
The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity
Winter, G. E., Radic, B., Mayor-Ruiz, C., Blomen, V. A., Trefzer, C., Kandasamy, R. K., Huber, K. V. M., Gridling, M., Chen, D., Klampfl, T., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1590 · Cited by 175 · cited 3×
“The example of SLC35F2 is very pertinent—the recognition of its activity in transporting sepantronium is new (Winter et al., 2014) but the transporter (albeit not its natural substrate) was known (Ishida and Kawakita, 2004; Song, 2013).”
BackgroundGABAA receptor subtypes: the ‘one glass of wine’ receptors
Olsen, R. W., Hanchar, H. J., Meera, P., & Wallner, M. (2007) · Alcohol · doi:10.1016/j.alcohol.2007.04.006 · Cited by 142 · cited 1×
“Another recently discovered binding protein for ethanol [additional to GABAA receptor subtypes (Wallner et al., 2003, 2006; Nutt et al., 2007; Olsen et al., 2007; Santhakumar et al., 2007; Bonin and Orser, 2008; Lobo and Harris, 2008; Mody, 2008; Meera et al., 2010; Johnson et al., 2012) and many…”
BackgroundDrug-grapefruit juice interactions
Pirmohamed, M. (2013) · BMJ · doi:10.1136/bmj.f1 · Cited by 140
Organic anion transporters and their implications in pharmacotherapy
Emami Riedmaier, A., Nies, A. T., Schaeffeler, E., & Schwab, M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004614 · Cited by 128 · cited 1×
“…König, 2011; Mruk et al., 2011; Nies et al., 2011; Thompson, 2011; Tirona, 2011; Zolk and Fromm, 2011; Degorter et al., 2012; Mandery et al., 2012; Riedmaier et al., 2012; Sprowl et al., 2012; Chu et al., 2013b; Estudante et al., 2013; Giacomini and Huang, 2013; Hagenbuch and Stieger, 2013; König…”
BackgroundDevelopment and evaluation of an in vitro method for prediction of human drug absorption
Corti, G., Maestrelli, F., Cirri, M., Zerrouk, N., & Mura, P. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.11.005 · Cited by 100 · cited 1×
“Our very first review (Dobson and Kell, 2008) displayed a typical example taken from a paper by Corti et al. (2006), showing that there is not, and we would like to stress that this paper was not specifically selected—it just happened to be the first paper we looked at for this question.”
BackgroundDirected evolution of an E. coli inner membrane transporter for improved efflux of biofuel molecules
Foo, J., & Leong, S. (2013) · Biotechnology for Biofuels · doi:10.1186/1754-6834-6-81 · Cited by 94
The BCS, BDDCS, and Regulatory Guidances
Chen, M.-L., Amidon, G. L., Benet, L. Z., Lennernas, H., & Yu, L. X. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0438-1 · Cited by 93 · cited 1×
“The Biopharmaceutics Classification System (BCS), based on the work of Amidon and colleagues (e.g., Amidon et al., 1995; Dahan et al., 2009; Chen et al., 2011), was developed to indicate a “bioequivalence,” and divides drugs into four classes based on their solubility and presumed (human jejunal)…”
MethodGABAA receptor subtypes underlying general anesthesia
Bonin, R. P., & Orser, B. A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.12.011 · Cited by 85
Tsamandouras, N., Dickinson, G., Guo, Y., Hall, S., Rostami-Hodjegan, A., Galetin, A., & Aarons, L. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.55 · Cited by 68
Howard, R. J., Trudell, J. R., & Harris, R. A. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.007468 · Cited by 56
Determinants of the Anesthetic Sensitivity of Two-pore Domain Acid-sensitive Potassium Channels
Andres-Enguix, I., Caley, A., Yustos, R., Schumacher, M. A., Spanu, P. D., Dickinson, R., Maze, M., & Franks, N. P. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610692200 · Cited by 52 · cited 1×
“…(Patel et al., 1999; Thompson and Wafford, 2001; Franks and Honoré, 2004; Gruss et al., 2004; Heurteaux et al., 2004; Grasshoff et al., 2006; Andres-Enguix et al., 2007; Bertaccini and Trudell, 2012), glycine receptors (Mihic et al., 1997; Lobo and Harris, 2005; Dickinson et al., 2007;…”
Background
Cited by
A Call for Systematic Research on Solute Carriers
César-Razquin, A., Snijder, B., Frappier-Brinton, T., Isserlin, R., Gyimesi, G., Bai, X., Reithmeier, R. A., Hepworth, D., Hediger, M. A., Edwards, A. M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.022 · Cited by 580
Kell, D. B., Heyden, E. L., & Pretorius, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01221 · Cited by 460
Self-citationThe association between sterilizing activity and drug distribution into tuberculosis lesions
Prideaux, B., Via, L. E., Zimmerman, M. D., Eum, S., Sarathy, J., O'Brien, P., Chen, C., Kaya, F., Weiner, D. M., Chen, P.-Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3937 · Cited by 461
Currin, A., Swainston, N., Day, P. J., & Kell, D. B. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00351a · Cited by 388
Self-citationThe dormant blood microbiome in chronic, inflammatory diseases
Potgieter, M., Bester, J., Kell, D. B., & Pretorius, E. (2015) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuv013 · Cited by 383
Self-citation
Metadata
- Authors
- Kell, D. B., & Oliver, S. G.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2014-10-31
- Volume
- 5
- Pages
- 231-231
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2010263368
- Cited by
- 156
- References
- 46
- FWCI
- 8.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.